<DOC>
	<DOCNO>NCT00274573</DOCNO>
	<brief_summary>The primary objective study investigate effect tiotropium vs. placebo trough FEV1 FEV1 2 hour post inhalation 12 week treatment . For endpoint change baseline analyse . Three stratum patient include ( severe COPD , i.e . &lt; 35 % predict FEV1 , moderate COPD , i.e . 35 % - &lt; 50 % predict FEV1 , mild COPD , i.e . 50 % - 70 % predict FEV1 , accord American Thoracic Society [ ATS ] criterion ) . The study conduct order find endpoint tiotropium different placebo stratum .</brief_summary>
	<brief_title>Effects Once Daily Tiotropium Patients With Chronic Obstructive Pulmonary Disease ( COPD ) Different Severity</brief_title>
	<detailed_description />
	<mesh_term>Lung Diseases</mesh_term>
	<mesh_term>Lung Diseases , Obstructive</mesh_term>
	<mesh_term>Pulmonary Disease , Chronic Obstructive</mesh_term>
	<mesh_term>Chronic Disease</mesh_term>
	<mesh_term>Bromides</mesh_term>
	<mesh_term>Tiotropium Bromide</mesh_term>
	<criteria>1 . All patient must diagnosis chronic obstructive pulmonary disease must meet follow spirometric criterion : Patients must relatively stable , mild severe airway obstruction FEV1 = &lt; 70 % predict normal FEV1/FVC &lt; 70 % . Predicted normal value take printouts spirometer . Spirometers calibrate accord ECCS . 2 . Male female patient 40 year age old . 3 . Patients must current exsmokers smoke history 10 10 packyears . Pack Years = Number cigarettes/day : 20 x year smoke ( Patients never smoke cigarette must include ) 4 . Patients must able perform study related test , acceptable pulmonary function test , include Peak Expiratory Flow Rate ( PEFR ) measurement , must able maintain diary card study period require protocol . 5 . Patients must able inhale medication HandiHaler . 6 . All patient must sign Informed Consent Form prior participation trial i.e . prior prestudy washout usual pulmonary medication . 1 . Patients significant disease COPD exclude . A significant disease define disease opinion investigator may either put patient risk participation study disease may influence result study patient 's ability participate study . 2 . Patients recent history ( i.e. , one year less ) myocardial infarction . 3 . Patients cardiac arrhythmia require drug therapy hospitalise heart failure within past three year . 4 . Patients regularly use daytime oxygen therapy 1 hour per day investigator 's opinion unable abstain use oxygen therapy . 5 . Patients know active tuberculosis . 6 . Patients history cancer within last five year . Patients treat basal cell carcinoma allow . 7 . Patients history lifethreatening pulmonary obstruction , history cystic fibrosis bronchiectasis . 8 . Patients undergone thoracotomy pulmonary resection . Patients history thoracotomy reason evaluate per exclusion 1 . 9 . Patients respiratory infection past six week prior Screening Visit ( Visit 1 ) runin period . 10 . Patients currently pulmonary rehabilitation programme complete pulmonary rehabilitation programme six week prior Screening Visit ( Visit 1 ) . 11 . Patients know hypersensitivity anticholinergic drug , lactose component inhalation capsule delivery system . 12 . Patients know symptomatic prostate hypertrophy bladder neck obstruction . 13 . Patients know narrowangle glaucoma . 14 . Patients use oral corticosteroid medication unstable dos ( i.e. , less four week stable dose Visit 1 ) dos excess equivalent 10 mg prednisolone per day 20 mg every day . 15 . Pregnant nursing woman woman childbearing potential use medically approve mean contraception ( i.e . oral contraceptive , intrauterine device , diaphragm subdermal implant ) . 16 . Patients history asthma , allergic rhinitis atopy . 17 . Patients history and/or active significant alcohol drug abuse . 18 . Patients take investigational drug within one month prior Screening Visit ( Visit 1 ) . A log subject screen , reason exclusion randomise maintain .</criteria>
	<gender>All</gender>
	<minimum_age>40 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2013</verification_date>
</DOC>